The Role and Implications of COVID-19 in Incident and Prevalent Heart Failure.

IF 3.8 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS

Current Heart Failure Reports Pub Date : 2024-10-01 Epub Date: 2024-07-23 DOI:10.1007/s11897-024-00677-7

Juan Simon Rico-Mesa, Justin Haloot, B K Anupama, Suman Atluri, Jing Liu, Umair Khalid

{"title":"The Role and Implications of COVID-19 in Incident and Prevalent Heart Failure.","authors":"Juan Simon Rico-Mesa, Justin Haloot, B K Anupama, Suman Atluri, Jing Liu, Umair Khalid","doi":"10.1007/s11897-024-00677-7","DOIUrl":null,"url":null,"abstract":"Purpose of review: This review examines the pathophysiological interactions between COVID-19 and heart failure, highlighting the exacerbation of heart failure in COVID-19 patients. It focuses on the complex mechanisms driving worse outcomes in these patients.Recent findings: Patients with pre-existing heart failure experience more severe symptoms and higher mortality rates due to mechanisms such as cytokine storms, myocardial infarction, myocarditis, microvascular dysfunction, thrombosis, and stress cardiomyopathy. Elevated biomarkers like troponin and natriuretic peptides correlate with severe disease. Long-term cardiovascular risks for COVID-19 survivors include increased incidence of heart failure, non-ischemic cardiomyopathy, cardiac arrest, and cardiogenic shock. COVID-19 significantly impacts patients with pre-existing heart failure, leading to severe symptoms and higher mortality. Elevated cardiac biomarkers are indicators of severe disease. Acute and long-term cardiovascular complications are common, calling for ongoing research into targeted therapies and improved management strategies to better prevent, diagnose, and treat heart failure in the context of COVID-19.","PeriodicalId":10830,"journal":{"name":"Current Heart Failure Reports","volume":" ","pages":"485-497"},"PeriodicalIF":3.8000,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Heart Failure Reports","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s11897-024-00677-7","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/7/23 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose of review: This review examines the pathophysiological interactions between COVID-19 and heart failure, highlighting the exacerbation of heart failure in COVID-19 patients. It focuses on the complex mechanisms driving worse outcomes in these patients.

Recent findings: Patients with pre-existing heart failure experience more severe symptoms and higher mortality rates due to mechanisms such as cytokine storms, myocardial infarction, myocarditis, microvascular dysfunction, thrombosis, and stress cardiomyopathy. Elevated biomarkers like troponin and natriuretic peptides correlate with severe disease. Long-term cardiovascular risks for COVID-19 survivors include increased incidence of heart failure, non-ischemic cardiomyopathy, cardiac arrest, and cardiogenic shock. COVID-19 significantly impacts patients with pre-existing heart failure, leading to severe symptoms and higher mortality. Elevated cardiac biomarkers are indicators of severe disease. Acute and long-term cardiovascular complications are common, calling for ongoing research into targeted therapies and improved management strategies to better prevent, diagnose, and treat heart failure in the context of COVID-19.

查看原文本刊更多论文

COVID-19 在心力衰竭发病率和流行率中的作用和意义。

综述目的：本综述探讨了 COVID-19 与心力衰竭之间的病理生理学相互作用，强调了 COVID-19 患者心力衰竭的加重。研究重点是导致这些患者预后恶化的复杂机制：最新研究结果：由于细胞因子风暴、心肌梗塞、心肌炎、微血管功能障碍、血栓形成和应激性心肌病等机制，原有心衰的患者会出现更严重的症状和更高的死亡率。肌钙蛋白和钠尿肽等生物标志物的升高与病情严重有关。COVID-19 存活者的长期心血管风险包括心力衰竭、非缺血性心肌病、心脏骤停和心源性休克的发病率增加。COVID-19 对原有心力衰竭的患者影响很大，会导致严重的症状和更高的死亡率。心脏生物标志物升高是病情严重的指标。急性和长期心血管并发症很常见，因此需要不断研究靶向疗法和改进管理策略，以便在 COVID-19 的背景下更好地预防、诊断和治疗心力衰竭。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current Heart Failure Reports Medicine-Emergency Medicine

CiteScore

5.30

自引率

0.00%

发文量

期刊介绍： This journal intends to provide clear, insightful, balanced contributions by international experts that review the most important, recently published clinical findings related to the diagnosis, treatment, management, and prevention of heart failure. We accomplish this aim by appointing international authorities to serve as Section Editors in key subject areas, such as investigative, pharmacologic, and nonpharmacologic therapies, pathophysiology, and prevention. Section Editors, in turn, select topics for which leading experts contribute comprehensive review articles that emphasize new developments and recently published papers of major importance, highlighted by annotated reference lists. An international Editorial Board reviews the annual table of contents, suggests articles of special interest to their country/region, and ensures that topics are current and include emerging research. Commentaries from well-known figures in the field are also provided.